Payment overview · 2025
General Payments
$49.71
2 reported records · 1 companies
Healthcare provider profile · identity verified
Tara A Clark, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BLUE SPRINGS, MO · NPI 1750345245
Verified facts
What the public records show
CMS Open Payments records show Tara A Clark, D.O. received $49.71 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Arexvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $49.71 | 100.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.71 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.71 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
53 | 53 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 559 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 529 | 137 |
| Pantoprazole Sodium | Pantoprazole Sodium | 368 | 96 |
| Omeprazole | Omeprazole | 350 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 349 | 88 |
| Losartan Potassium | Losartan Potassium | 341 | 89 |
| Lisinopril | Lisinopril | 327 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 316 | 78 |
| Gabapentin | Gabapentin | 219 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 216 | 49 |
| Sertraline Hcl | Sertraline Hcl | 209 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 177 | 44 |
| Metformin Hcl | Metformin Hcl | 163 | 36 |
| Montelukast Sodium | Montelukast Sodium | 162 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 62 |
| Alprazolam | Alprazolam | 144 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 25 |
| Meloxicam | Meloxicam | 118 | 34 |
| Trazodone Hcl | Trazodone Hcl | 117 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 111 | 38 |
| Metformin Hcl Er | Metformin Hcl | 106 | 27 |
| Ozempic | Semaglutide | 106 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 41 |
| Simvastatin | Simvastatin | 100 | 28 |
| Alendronate Sodium | Alendronate Sodium | 94 | 22 |
| Allopurinol | Allopurinol | 93 | 21 |
| Methylprednisolone | Methylprednisolone | 89 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | 18 |
| Celecoxib | Celecoxib | 70 | 18 |
| Eliquis | Apixaban | 70 | 12 |
| Tramadol Hcl | Tramadol Hcl | 62 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 16 |
| Furosemide | Furosemide | 59 | 15 |
| Carvedilol | Carvedilol | 56 | 12 |
| Potassium Chloride | Potassium Chloride | 55 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 53 | 53 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 43 |
| Azelastine Hcl | Azelastine Hcl | 51 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Glipizide Er | Glipizide | 47 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 46 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 13 |
| Ezetimibe | Ezetimibe | 44 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 13 |
| Topiramate | Topiramate | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 41 | 12 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Estradiol | Estradiol | 38 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 11 |
| Glipizide | Glipizide | 37 | 11 |
| Spironolactone | Spironolactone | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 13 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | 11 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Lorazepam | Lorazepam | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 22 |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 23 |
| Finasteride | Finasteride | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 22 |
| Telmisartan | Telmisartan | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 18 |
| Prednisone | Prednisone | 19 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Nystatin | Nystatin | 14 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.71 · 2 records | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error